No title available
This is a promising phase I study from the University of Utah combining ruxolitinib and selinexor for frontline therapy of myelofibrosis.
Related Articles
How a Colorectal Cancer Diagnosis Became the Best/Worst Thing to Happen to Gina
CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of the cancer experience.
Sacituzumab Tirumotecan Shows Early Efficacy in Gastric/GEJ Cancers
Sacituzumab tirumotecan elicited responses prominently in the second- and third-line and beyond setting and in those with high TROP2 expression.
The Rise and Risks of Medicare Advantage “Affinity Plans”
This Viewpoint discusses the proliferation of Medicare Advantage plans targeting specific groups of individuals and whether these plans will improve quality of care for beneficiaries.
Bailey Roberts, MD – Best of the Best in Pediatric Surgery 2024
Watch IPSO’s Dr. Bailey Roberts’s presentation on “Extracellular vesicles from metastatic osteosarcoma contribute…
Building stronger evidence ecosystems together: Cochrane, JBI, and Campbell’s call to action
We are thrilled to announce the publication of a new editorial titled “Unlocking the Power of Global Collaboration: Building a Stronger Evidence Ecosystem Together,” authored…
Residential and healthcare mobility during pregnancy among women living with HIV in the UK, 2009–2019
Introduction The extent to which individuals living with HIV experience residential and healthcare mobility during pregnancy in the UK is unknown. We aimed to determine…
Prevalence of HIV drug resistance at antiretroviral treatment failure across regions of Russia
Background This study aimed to investigate mutations associated with, the causes of, and the conditions that contribute to HIV drug resistance (DR). This research provides…